CB-5083 is a novel, potent, selective, first in class and orally bioavailable p97 AAA ATPase inhibitor with potential anticancer activity.

CGK 733 is a novel, potent and selective inhibitor of ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related) with the potential to treat Hepatocellular carcinoma (HCC).

Schisandrin B (γ-Schisandrin; Sch B) is a naturally occuring and the most abundant dibenzocyclooctadiene lignan isolated from traditional Chinese medicinal herb Schisandra chinensis (Turcz.) with antioxidant effect on rodent liver and heart.

SKLB 197 is a novel and potent ATR inhibitor (IC50 =0.013 μM).

AZ31 (AZ-31; AZ 31) is a novel, potent and orally bioavailable and BBB (blood-brain barrier)-penetreable ATM inhibitor with antitumor activity.

KU-55933 is a potent and specific ATM (Ataxia-telangiectasia mutated) kinase inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

AZ20 is a novel potent and selective inhibitor of ATR (ATM and Rad3-related) protein kinase with potential antitumor activity.

AZ32 is a novel, potent and orally bioavailable and blood-brain barrier-penetreable ATM inhibitor (AZ32) that radiosensitizes intracranial gliomas in mice.

Ceralasertib (formerly AZD6738), a morpholino-pyrimidine-based DNA damage repair agent, is a potent, orally bioavailable and selective inhibitor of ATR (ataxia telangiectasia and rad3 related) kinase with potential antitumor activity.

ETP-46464 (ETP46464) is a novel, potent and selective inhibitor of ATR (Ataxia-telangiectasia mutated) and mTOR (mammalian target of rapamycin) with potential anticancer activity.